1. Home
  2. NCNO vs NAMS Comparison

NCNO vs NAMS Comparison

Compare NCNO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCNO
  • NAMS
  • Stock Information
  • Founded
  • NCNO 2011
  • NAMS 2019
  • Country
  • NCNO United States
  • NAMS Netherlands
  • Employees
  • NCNO N/A
  • NAMS N/A
  • Industry
  • NCNO Computer Software: Prepackaged Software
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCNO Technology
  • NAMS Health Care
  • Exchange
  • NCNO Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • NCNO 3.2B
  • NAMS 2.7B
  • IPO Year
  • NCNO 2020
  • NAMS N/A
  • Fundamental
  • Price
  • NCNO $30.09
  • NAMS $24.19
  • Analyst Decision
  • NCNO Buy
  • NAMS Strong Buy
  • Analyst Count
  • NCNO 16
  • NAMS 10
  • Target Price
  • NCNO $34.40
  • NAMS $41.40
  • AVG Volume (30 Days)
  • NCNO 2.4M
  • NAMS 1.0M
  • Earning Date
  • NCNO 08-26-2025
  • NAMS 11-05-2025
  • Dividend Yield
  • NCNO N/A
  • NAMS N/A
  • EPS Growth
  • NCNO N/A
  • NAMS N/A
  • EPS
  • NCNO N/A
  • NAMS N/A
  • Revenue
  • NCNO $573,119,000.00
  • NAMS $64,006,000.00
  • Revenue This Year
  • NCNO $9.70
  • NAMS N/A
  • Revenue Next Year
  • NCNO $8.80
  • NAMS N/A
  • P/E Ratio
  • NCNO N/A
  • NAMS N/A
  • Revenue Growth
  • NCNO 13.24
  • NAMS 762.15
  • 52 Week Low
  • NCNO $18.75
  • NAMS $14.06
  • 52 Week High
  • NCNO $43.20
  • NAMS $27.35
  • Technical
  • Relative Strength Index (RSI)
  • NCNO 52.83
  • NAMS 47.32
  • Support Level
  • NCNO $29.61
  • NAMS $24.18
  • Resistance Level
  • NCNO $31.93
  • NAMS $27.35
  • Average True Range (ATR)
  • NCNO 1.21
  • NAMS 1.40
  • MACD
  • NCNO -0.05
  • NAMS -0.07
  • Stochastic Oscillator
  • NCNO 36.80
  • NAMS 13.42

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: